Developer docs
API playgroundTry for free, no card

Search company profiles

BioXtek

Full company profile

uuid00kd7wp

Namestring
BioXtek
Legal namestring
BioXtek LLC
Websiteurl
bioxtek.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

BioXtek is a Pompano Beach, Florida-based regenerative therapeutics manufacturer founded in 2022 that develops biologic products derived from qualified single-birth placental and umbilical cord donors. The company operates an 11,000 sqft FDA-registered, AATB-accredited, cGMP/cGTP-compliant facility with ISO-rated cleanrooms and SAL 10⁻⁶ terminal sterilization capability, producing placental membrane patches (Sanoplast DHAAM, Sanoplast Duo), umbilical cord products (Sanoplast UAP, CordGuardECM), stem cell therapeutics (BioXcells in 10M and 25M cell vials), exosome therapeutics (BioXsomes), and a cosmetic serum (BioXjel+). At the core is the proprietary BioPūr Process, which preserves bioactive molecules including exosomes, growth factors, peptides, cytokines, miRNA, and the HC-HA/PTX3 complex while stripping endotoxins and immunogenic triggers from a cell-free extracellular matrix.

BioXtek commercializes through a sales-led GTM motion combining direct sales and a distributor network to reach healthcare providers, surgeons, pain management specialists, longevity clinics, and medi-spas across multiple U.S. states, with state-level tissue banking licensure secured in Florida, Delaware, Oregon, California, Illinois, Maryland, and New York. The company monetizes via one-time product sales (pricing undisclosed) with documented clinical outcomes including a 4x reduction in postoperative atrial fibrillation (8.3% vs 35.2%), 90% chronic wound healing at 12 weeks, and VAS pain score improvement from 8.2 to 2.3. In April 2026, BioXtek signed a non-binding LOI with Exo-Top Inc., the U.S. subsidiary of NurExone Biologic, to explore contract manufacturing and commercialization of bone marrow-derived MSC exosomes targeting the projected $1.6B+ regenerative aesthetics market by 2034 and potentially supporting NurExone's ExoPTEN clinical program.

The company is privately held as BioXtek LLC, employs 11-50 people, and is led by CEO Bruce Werber (board-certified reconstructive surgeon, 35+ years), Co-Founder Terrell Suddarth, CFO/COO Carmen Kerschbaum (12+ years at Pfizer and Roche), Commercial Lead Linda Liguore (former Repicon founder, scaled to $21M), and Medical Director Michael J. Bauer, with academic advisors from University of Arizona and Tulane. Revenue is not publicly disclosed; reimbursement depends on Medicare and private payer coverage policies for HCT/P products.

Short descriptiontext

BioXtek is a Pompano Beach, FL-based regenerative therapeutics manufacturer founded in 2022 that uses its proprietary BioPūr Process to produce FDA-registered placental membrane patches, stem cell, and exosome products sold to healthcare providers, surgeons, and medi-spas across multiple U.S. states.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPompano Beach, United States
HQ citystring
Pompano Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative therapeutics, placental tissue products, biologic manufacturing, exosome therapeutics, wound care solutions
Industry2 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Regenerative Biologics Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Placental Membrane Patches
TypeOne Time License
Description

Sale of placental membrane patches (Sanoplast ECM, Sanoplast Duo) as FDA 1271/361 HCT/P products. Available in multiple configurations from single layer to quad layer, sized from 2x2cm to 15x20cm.

bioxtek.com
2Umbilical Cord Products
TypeOne Time License
Description

Sale of umbilical cord derived products including Sanoplast UAP (human umbilical cord powder) and CordGuardECM (human umbilical cord patches) for wound care and tissue support applications.

bioxtek.com
3Stem Cell and Exosome Therapeutics
TypeOne Time License
Description

Sale of BioXcells stem cell products (10M and 25M cell vials with 90% viability guaranteed) and BioXsomes exosome therapeutics for Florida physicians to treat Pain, Wounds, and Orthopedic complaints.

bioxtek.com
4Cosmetic Products (BioXjel+)
TypeOne Time License
bioxtek.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Sanoplast DHAAM
Description

Dehydrated and/or lyophilized placental membrane patches registered as FDA 1271/361 barriers and covers.

bioxtek.com
+6 more records
Core offering1 text field

BioXtek develops and manufactures biologic regenerative products derived from human placental and umbilical cord tissue. Its portfolio includes placental membrane patches (Sanoplast DHAAM), umbilical cord patches and powder (CordGuardECM, Sanoplast UAP), stem cell vials (BioXcells), exosome therapeutics (BioXsomes), and a topical cosmetic serum (BioXjel+). Products are manufactured at an FDA-registered, AATB-accredited 11,000 sqft cGMP facility using the proprietary BioPür Process and sold to physicians, surgeons, longevity clinics, and medi-spas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 4x reduction in postoperative atrial fibrillation (POAF) incidence: 8.3% vs 35.2% (p=0.0136) in cardiac surgery pilot study
+4 more records
Product and service6 records
1Sanoplast DHAAM (Dehydrated Human Amniotic Membrane)
CategoryPlacental Membrane Patches
Description

Dehydrated and/or lyophilized placental membrane patches available in single to quad layer configurations sized from 2x2cm to 15x20cm, registered as FDA 1271/361 HCT/P products for wound care, surgical applications, dura replacement, tendon/nerve repair, and cardiac surgery. Sold to healthcare providers and surgeons.

2BioXsomes
CategoryExosome Therapeutics
Description

Fluid implantable acellular exosome therapeutic product sold to Florida-licensed physicians for treating pain, wounds, and orthopedic complaints.

3BioXjel+
CategoryCosmetic Serum
Description

Topical cosmetic serum derived from Wharton's jelly and amniotic fluid for facial aesthetics, hair aesthetics, topical scar application, and collagen stimulation. Sold to longevity clinics, medi-spas, and licensed professionals.

4BioXcells
CategoryStem Cell Therapeutics
Description

Stem cell product available in 10M and 25M cell vials with 90% viability guaranteed, offered to Florida physicians for pain, wounds, and orthopedic complaints.

5CordGuardECM
CategoryUmbilical Cord Patches
Description

Human umbilical cord patches for wound care and tissue support applications. Sold to healthcare providers.

6Sanoplast UAP
CategoryUmbilical Cord Powder
Description

Human umbilical cord powder product for wound care and tissue support applications. Sold to healthcare providers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Exo-Top Inc. (NurExone Biologic subsidiary)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Exo-Top Inc., the U.S. subsidiary of NurExone Biologic Inc., signed a non-binding Letter of Intent with Florida-based BioXtek Inc. on April 7, 2026 to explore a strategic partnership for manufacturing and commercializing bone marrow-derived mesenchymal stem cell exosomes. The collaboration aims to combine Exo-Top's proprietary Master Cell Bank and exosome production expertise with BioXtek's U.S. GMP manufacturing infrastructure to support clinical supply and expand production capacity. The partnership targets the rapidly growing exosome-based regenerative aesthetics market projected to surpass $1.6 billion by 2034, and may also support clinical trials for NurExone's lead drug candidate ExoPTEN targeting acute spinal cord injury and optic nerve damage.

stocktitan.net
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Organogenesis manufactures and commercializes regenerative wound care biologics (Apligraf, Dermagraft, PuraPly) and surgical biologics (NuCel) — overlapping with BioXtek's placental membrane and umbilical cord product lines in the same HCT/P/commercial biologics category.

TypeEmerging player
Description

Celularity develops placental-derived cellular and regenerative therapies, leveraging the same birth-tissue donor model as BioXtek. Direct overlap in placental-derived biologics for wound care and aesthetics applications.

TypeBroad incumbent
Description

Smith+Nephew is a large diversified wound care and orthopedics incumbent offering skin substitutes, advanced wound dressings, and regenerative solutions — competing with BioXtek in wound care while also serving as a benchmark for sales/distribution scale in the same end markets.

TypeDirect peer
Description

MiMedx is the largest U.S. marketer of dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for wound care and surgical applications — directly competing with BioXtek's Sanoplast placental membrane patches across the same physician channels and HCT/P regulatory pathway.

5NurExone Biologic
TypeEmerging player
Description

NurExone Biologic is the publicly-listed parent of Exo-Top, BioXtek's announced LOI partner. NurExone develops exosome-based therapeutics for spinal cord and optic nerve injury — sharing BioXtek's exosome manufacturing focus and serving as both a strategic partner and emerging exosome peer.

TypeBroad incumbent
Description

Integra LifeSciences markets regenerative wound care and dural repair products (DuraGen, Integra Dermal Regeneration Template) — directly overlapping BioXtek's dura replacement and wound healing indications with a broader surgical specialty portfolio.

TypeEmerging player
Description

Vericel develops and commercializes autologous cell therapies (MACI for cartilage repair, Epicel for burns) — sharing BioXtek's regenerative medicine orientation, surgical biologics channel, and orthopedics/burn indications.

TypeBroad incumbent
Description

Osiris was a pioneer in mesenchymal stem cell products (Grafix, OvationOS) for wound care and orthopedics, now part of Smith+Nephew — overlapping BioXtek's stem cell and placental-derived approaches in the same physician channels.

TypeEmerging player
Description

Direct Biologics develops bone marrow-derived mesenchymal stem cell and exosome products for orthopedic, wound, and inflammatory indications — sharing BioXtek's MSC-derived exosome focus and competing for the same Florida aesthetics and orthopedic accounts.

TypeBroad incumbent
Description

Stryker is a large medtech incumbent with orthopedics, surgical, and wound care portfolios that compete broadly with BioXtek's orthopedic and surgical applications of placental membrane patches.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioXtek

Regenerative Biologics Manufacturingbioxtek.com

BioXtek is a Pompano Beach, FL-based regenerative therapeutics manufacturer founded in 2022 that uses its proprietary BioPūr Process to produce FDA-registered placental membrane patches, stem cell, and exosome products sold to healthcare providers, surgeons, and medi-spas across multiple U.S. states.

What BioXtek does

BioXtek is a Pompano Beach, Florida-based regenerative therapeutics manufacturer founded in 2022 that develops biologic products derived from qualified single-birth placental and umbilical cord donors. The company operates an 11,000 sqft FDA-registered, AATB-accredited, cGMP/cGTP-compliant facility with ISO-rated cleanrooms and SAL 10⁻⁶ terminal sterilization capability, producing placental membrane patches (Sanoplast DHAAM, Sanoplast Duo), umbilical cord products (Sanoplast UAP, CordGuardECM), stem cell therapeutics (BioXcells in 10M and 25M cell vials), exosome therapeutics (BioXsomes), and a cosmetic serum (BioXjel+). At the core is the proprietary BioPūr Process, which preserves bioactive molecules including exosomes, growth factors, peptides, cytokines, miRNA, and the HC-HA/PTX3 complex while stripping endotoxins and immunogenic triggers from a cell-free extracellular matrix.

BioXtek commercializes through a sales-led GTM motion combining direct sales and a distributor network to reach healthcare providers, surgeons, pain management specialists, longevity clinics, and medi-spas across multiple U.S. states, with state-level tissue banking licensure secured in Florida, Delaware, Oregon, California, Illinois, Maryland, and New York. The company monetizes via one-time product sales (pricing undisclosed) with documented clinical outcomes including a 4x reduction in postoperative atrial fibrillation (8.3% vs 35.2%), 90% chronic wound healing at 12 weeks, and VAS pain score improvement from 8.2 to 2.3. In April 2026, BioXtek signed a non-binding LOI with Exo-Top Inc., the U.S. subsidiary of NurExone Biologic, to explore contract manufacturing and commercialization of bone marrow-derived MSC exosomes targeting the projected $1.6B+ regenerative aesthetics market by 2034 and potentially supporting NurExone's ExoPTEN clinical program.

The company is privately held as BioXtek LLC, employs 11-50 people, and is led by CEO Bruce Werber (board-certified reconstructive surgeon, 35+ years), Co-Founder Terrell Suddarth, CFO/COO Carmen Kerschbaum (12+ years at Pfizer and Roche), Commercial Lead Linda Liguore (former Repicon founder, scaled to $21M), and Medical Director Michael J. Bauer, with academic advisors from University of Arizona and Tulane. Revenue is not publicly disclosed; reimbursement depends on Medicare and private payer coverage policies for HCT/P products.

BioXtek firmographics

Firmographics
Name
BioXtek
Legal name
BioXtek LLC
Website
https://bioxtek.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
BioXtek is a Pompano Beach, FL-based regenerative therapeutics manufacturer founded in 2022 that uses its proprietary BioPūr Process to produce FDA-registered placental membrane patches, stem cell, and exosome products sold to healthcare providers, surgeons, and medi-spas across multiple U.S. states.
Ownership category
akta.pro rank

BioXtek industry classification

Industry
Product category
Regenerative Biologics Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Regenerative therapeutics
  • Placental tissue products
  • Biologic manufacturing
  • Exosome therapeutics
  • Wound care solutions

Where BioXtek is headquartered

Location

Headquarters

HQ city
Pompano Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioXtek business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Placental Membrane Patches: Sale of placental membrane patches (Sanoplast ECM, Sanoplast Duo) as FDA 1271/361 HCT/P products. Available in multiple configurations from single layer to quad layer, sized from 2x2cm to 15x20cm.
  2. Umbilical Cord Products: Sale of umbilical cord derived products including Sanoplast UAP (human umbilical cord powder) and CordGuardECM (human umbilical cord patches) for wound care and tissue support applications.
  3. Stem Cell and Exosome Therapeutics: Sale of BioXcells stem cell products (10M and 25M cell vials with 90% viability guaranteed) and BioXsomes exosome therapeutics for Florida physicians to treat Pain, Wounds, and Orthopedic complaints.
  4. Cosmetic Products (BioXjel+):

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

BioXtek product offering

Product offering

Core offering

BioXtek develops and manufactures biologic regenerative products derived from human placental and umbilical cord tissue. Its portfolio includes placental membrane patches (Sanoplast DHAAM), umbilical cord patches and powder (CordGuardECM, Sanoplast UAP), stem cell vials (BioXcells), exosome therapeutics (BioXsomes), and a topical cosmetic serum (BioXjel+). Products are manufactured at an FDA-registered, AATB-accredited 11,000 sqft cGMP facility using the proprietary BioPür Process and sold to physicians, surgeons, longevity clinics, and medi-spas.

Differentiator

Problem solved

Functional benefit

Brands

  • Sanoplast DHAAM: Dehydrated and/or lyophilized placental membrane patches registered as FDA 1271/361 barriers and covers.
  • BioXsomes
  • BioXjel+
  • BioXcells
  • BioPür Process
  • CordGuardECM
  • Sanoplast UAP

Products and services

  • Sanoplast DHAAM (Dehydrated Human Amniotic Membrane) Dehydrated and/or lyophilized placental membrane patches available in single to quad layer configurations sized from 2x2cm to 15x20cm, registered as FDA 1271/361 HCT/P products for wound care, surgical applications, dura replacement, tendon/nerve repair, and cardiac surgery. Sold to healthcare providers and surgeons.
  • BioXsomes Fluid implantable acellular exosome therapeutic product sold to Florida-licensed physicians for treating pain, wounds, and orthopedic complaints.
  • BioXjel+ Topical cosmetic serum derived from Wharton's jelly and amniotic fluid for facial aesthetics, hair aesthetics, topical scar application, and collagen stimulation. Sold to longevity clinics, medi-spas, and licensed professionals.
  • BioXcells Stem cell product available in 10M and 25M cell vials with 90% viability guaranteed, offered to Florida physicians for pain, wounds, and orthopedic complaints.
  • CordGuardECM Human umbilical cord patches for wound care and tissue support applications. Sold to healthcare providers.
  • Sanoplast UAP Human umbilical cord powder product for wound care and tissue support applications. Sold to healthcare providers.

Quantifiable outcome

  • 4x reduction in postoperative atrial fibrillation (POAF) incidence: 8.3% vs 35.2% (p=0.0136) in cardiac surgery pilot study
  • +4 more outcomes

Companies that use BioXtek

Customer profile

Segments3 records

Ideal customer profiles3 records

BioXtek technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BioXtek partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Exo-Top Inc. (NurExone Biologic subsidiary)coreStrategic or Co-development Partner · 7 April 2026Exo-Top Inc., the U.S. subsidiary of NurExone Biologic Inc., signed a non-binding Letter of Intent with Florida-based BioXtek Inc. on April 7, 2026 to explore a strategic partnership for manufacturing and commercializing bone marrow-derived mesenchymal stem cell exosomes. The collaboration aims to combine Exo-Top's proprietary Master Cell Bank and exosome production expertise with BioXtek's U.S. GMP manufacturing infrastructure to support clinical supply and expand production capacity. The partnership targets the rapidly growing exosome-based regenerative aesthetics market projected to surpass $1.6 billion by 2034, and may also support clinical trials for NurExone's lead drug candidate ExoPTEN targeting acute spinal cord injury and optic nerve damage.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

BioXtek competitors and assessment

Company assessment

Direct peers

  • Organogenesis: Organogenesis manufactures and commercializes regenerative wound care biologics (Apligraf, Dermagraft, PuraPly) and surgical biologics (NuCel) — overlapping with BioXtek's placental membrane and umbilical cord product lines in the same HCT/P/commercial biologics category.
  • MiMedx Group: MiMedx is the largest U.S. marketer of dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for wound care and surgical applications — directly competing with BioXtek's Sanoplast placental membrane patches across the same physician channels and HCT/P regulatory pathway.

Emerging players

  • Celularity: Celularity develops placental-derived cellular and regenerative therapies, leveraging the same birth-tissue donor model as BioXtek. Direct overlap in placental-derived biologics for wound care and aesthetics applications.
  • NurExone Biologic: NurExone Biologic is the publicly-listed parent of Exo-Top, BioXtek's announced LOI partner. NurExone develops exosome-based therapeutics for spinal cord and optic nerve injury — sharing BioXtek's exosome manufacturing focus and serving as both a strategic partner and emerging exosome peer.
  • Vericel: Vericel develops and commercializes autologous cell therapies (MACI for cartilage repair, Epicel for burns) — sharing BioXtek's regenerative medicine orientation, surgical biologics channel, and orthopedics/burn indications.
  • Direct Biologics: Direct Biologics develops bone marrow-derived mesenchymal stem cell and exosome products for orthopedic, wound, and inflammatory indications — sharing BioXtek's MSC-derived exosome focus and competing for the same Florida aesthetics and orthopedic accounts.

Broad incumbents

  • Smith+Nephew: Smith+Nephew is a large diversified wound care and orthopedics incumbent offering skin substitutes, advanced wound dressings, and regenerative solutions — competing with BioXtek in wound care while also serving as a benchmark for sales/distribution scale in the same end markets.
  • Integra LifeSciences: Integra LifeSciences markets regenerative wound care and dural repair products (DuraGen, Integra Dermal Regeneration Template) — directly overlapping BioXtek's dura replacement and wound healing indications with a broader surgical specialty portfolio.
  • Osiris Therapeutics (Smith+Nephew): Osiris was a pioneer in mesenchymal stem cell products (Grafix, OvationOS) for wound care and orthopedics, now part of Smith+Nephew — overlapping BioXtek's stem cell and placental-derived approaches in the same physician channels.
  • Stryker: Stryker is a large medtech incumbent with orthopedics, surgical, and wound care portfolios that compete broadly with BioXtek's orthopedic and surgical applications of placental membrane patches.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

BioXtek social profiles

Digital presence

BioXtek financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioXtek leadership team

Management profile

Number of profiles

Profiles8 records

BioXtek funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioXtek M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioXtek

What does BioXtek do?

BioXtek develops and manufactures biologic regenerative products derived from human placental and umbilical cord tissue. Its portfolio includes placental membrane patches (Sanoplast DHAAM), umbilical cord patches and powder (CordGuardECM, Sanoplast UAP), stem cell vials (BioXcells), exosome therapeutics (BioXsomes), and a topical cosmetic serum (BioXjel+). Products are manufactured at an FDA-registered, AATB-accredited 11,000 sqft cGMP facility using the proprietary BioPür Process and sold to physicians, surgeons, longevity clinics, and medi-spas.

Is BioXtek a public or private company?

BioXtek is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioXtek founded?

BioXtek was founded in 2022. It employs 11 to 50 people.

Where is BioXtek based?

BioXtek is headquartered in Pompano Beach, United States, in the North America region.

How does BioXtek make money?

Four revenue lines are on record. Placental Membrane Patches are the primary driver. The others are umbilical Cord Products, stem Cell and Exosome Therapeutics and cosmetic Products (BioXjel+).

Who are BioXtek's main competitors?

Direct peers on record are Organogenesis and MiMedx Group. Emerging players are Celularity, NurExone Biologic, Vericel and Direct Biologics. Broad incumbents are Smith+Nephew, Integra LifeSciences, Osiris Therapeutics (Smith+Nephew) and Stryker.

Does BioXtek have an API?

No public API is recorded for BioXtek.

What industry is BioXtek in?

BioXtek's product category is Regenerative Biologics Manufacturing. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deNurExone stellt Weichen für den US-Markt: Exklusive GMP-Partnerschaft soll Produktion und Kommerzialisierung beschleunigenNurExone Biologic Inc. and its US subsidiary Exo-Top Inc. have signed a binding Memorandum of Understanding with Made Scientific, Inc. to establish an exclusive partnership for Good Manufacturing Practice (GMP) production and commercial supply of exosomes in the United States. This strategic move replaces previous plans with BioXtek Inc. and aims to secure scalable manufacturing capabilities by targeting the production of the first GMP-compliant batches in the first half of 2027.Stock TitanNurExone Signs Binding U.S. GMP Partnership MOUNurExone Biologic Inc. and its U.S. subsidiary Exo-Top Inc. have signed a binding memorandum of understanding with Made Scientific, Inc. to establish an exclusive U.S. Good Manufacturing Practice partnership for the manufacturing and commercial supply of exosome-based therapies. The agreement targets the initiation of the first GMP exosome batches in the first half of 2027 to support NurExone's clinical pipeline and future commercial production. Concurrently, NurExone announced it has mutually agreed to terminate a previous non-binding letter of intent with BioXtek Inc. to consolidate its U.S. manufacturing strategy under the new Made Scientific collaboration.FinanzNachrichten.deNurExone bringt Entwicklung, Finanzierung und US-Ausbau voranNurExone Biologic Inc. reported Q1 2026 results showing continued investment in exosome-based therapy development, with R&D costs of US$0.63 million and a widened net loss of US$1.77 million compared to US$1.68 million in the prior year period. The company secured approximately US$642 thousand through a non-brokered private placement in March 2026 and signed a sublicense agreement between its subsidiaries Exo-Top Inc. and NurExone Biologic Ltd. to support manufacturing and commercialization activities for naive exosomes in North America. Additionally, Exo-Top signed a non-binding letter of intent with Florida-based BioXtek Inc. on April 7, 2026, to explore a potential manufacturing and commercialization partnership.Stock TitanNurExone Q1 2026 loss $1.77M, LOI on US exosomesNurExone Biologic Inc. reported a Q1 2026 net loss of $1.77 million, up from a $1.68 million loss in the same quarter of 2025, reflecting modestly higher operating expenses. The company announced several corporate milestones including a sublicense agreement with its U.S. subsidiary Exo-Top Inc. and a non-binding letter of intent with Florida-based BioXtek Inc. to explore a strategic partnership for exosome manufacturing and commercialization in North America. NurExone also reported positive developments including an Australian patent grant for its extracellular vesicle production technology and batch-consistency results from proteomic analysis at Technion, advancing its regulatory and manufacturing roadmap toward a potential investigational new drug application.GlobeNewswireAustralian Patent Granted to NurExone Covering Stem Cell-Derived Exosome ProductionNurExone Biologic received an Australian patent for stem cell-derived exosome production on April 23, 2026, held by Technion Research and Development Foundation. The patent, valid until June 10, 2040, supports scalable exosome manufacturing and follows prior grants in Israel and the U.S. The company also announced a scientific presentation on ExoPTEN's regenerative potential in optic nerve damage.Stock TitanNurExone 2025 cash rises to $2.14M after $5.9M raiseNurExone Biologic Inc. reported full-year 2025 financial results showing a net loss of $6.38 million, up from $5.04 million in 2024, reflecting increased R&D investment in its ExoPTEN exosome therapy for CNS injuries. The company raised approximately $5.9 million through multiple private placements and warrant exercises in 2025, ending the year with cash of $2.14 million compared to $0.70 million at the end of 2024. The company also established its U.S. subsidiary Exo-Top and signed a non-binding LOI with Florida-based BioXtek Inc. to explore potential U.S. GMP manufacturing and commercialization of naïve exosomes.BioSpaceNurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate UpdateNurExone Biologic reported Q4 and full-year 2025 results, with a net loss of US$6.38 million and cash of US$2.14 million. The company raised about US$5.9 million in 2025 and plans to advance its ExoPTEN therapy toward first-in-human clinical trials.Stock TitanNurExone unit signs U.S. exosome manufacturing LOINurExone Biologic's wholly owned U.S. subsidiary Exo-Top has signed a non-binding Letter of Intent with Florida-based BioXtek to explore a strategic partnership for manufacturing and commercializing bone marrow-derived mesenchymal stem cell exosomes. The collaboration aims to combine Exo-Top's proprietary Master Cell Bank and exosome production expertise with BioXtek's U.S. GMP manufacturing infrastructure to support clinical supply and expand production capacity. The partnership targets the rapidly growing exosome-based regenerative aesthetics market projected to surpass $1.6 billion by 2034, and may also support clinical trials for NurExone's lead drug candidate ExoPTEN targeting acute spinal cord injury and optic nerve damage.